COPD Clinical Trials Overview

This study is a randomized, double-blind, placebo-controlled, parallel group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

Study number:

EFC16750: Former smokers

EFC16819: Current (20%) and former smokers (80%)

  • The study will include 114 sites.
  • The population being studied includes participants who are 40-85 years old with a diagnosis of COPD for at least 1 year, and a smoking history of ≥10 pack-years
  • Parameters of the study:
    • Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for 52 weeks
    • Evaluate the efficacy of itepekimab compared with placebo on pulmonary function in former smokers with moderate-to-severe COPD

Share this opportunity with colleagues who may be interested in being a principal investigator for this clinical trial.